VolitionRX’s (VNRX) Buy Rating Reaffirmed at D. Boral Capital

VolitionRX (NYSEAMERICAN:VNRX)‘s stock had its “buy” rating restated by D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $3.00 target price on the medical research company’s stock.

Separately, Maxim Group cut VolitionRX from a “buy” rating to a “hold” rating in a report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, VolitionRX currently has a consensus rating of “Buy” and an average target price of $2.50.

VolitionRX Trading Down 0.2%

Shares of NYSEAMERICAN:VNRX traded down $0.00 on Thursday, reaching $0.19. 8,709,157 shares of the company’s stock were exchanged, compared to its average volume of 11,239,004. VolitionRX has a twelve month low of $0.17 and a twelve month high of $0.94. The company has a fifty day moving average of $0.23 and a 200-day moving average of $0.35. The company has a market capitalization of $25.89 million, a price-to-earnings ratio of -0.83 and a beta of 1.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VNRX. Northwestern Mutual Wealth Management Co. acquired a new position in VolitionRX during the second quarter worth about $52,000. Armistice Capital LLC increased its position in VolitionRX by 3.5% during the 2nd quarter. Armistice Capital LLC now owns 8,493,074 shares of the medical research company’s stock worth $6,455,000 after purchasing an additional 286,644 shares in the last quarter. Silverberg Bernstein Capital Management LLC lifted its stake in VolitionRX by 15.6% in the 3rd quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the medical research company’s stock valued at $157,000 after purchasing an additional 31,300 shares during the last quarter. Virtu Financial LLC acquired a new stake in VolitionRX in the third quarter valued at approximately $28,000. Finally, Citadel Advisors LLC grew its stake in shares of VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after buying an additional 135,775 shares during the last quarter. Institutional investors own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.